{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047702","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.099401+00:00","generated_at":"2026-05-24T02:17:35.943609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline","bullets":["Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.","Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.","Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.","R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.","Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047702","json":"https://secwatch.observer/filing/0000950170-25-047702.json","markdown":"https://secwatch.observer/filing/0000950170-25-047702.md","text":"https://secwatch.observer/filing/0000950170-25-047702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/0000950170-25-047702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/srzn-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:17:35.943609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}